- Home
- PETS vs ACRS Comparison
PETS vs ACRS Comparison
Compare PETS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ACRS
- Stock Information
- Founded
- PETS 1996
- ACRS 2012
- Country
- PETS United States
- ACRS United States
- Employees
- PETS N/A
- ACRS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ACRS Health Care
- Exchange
- PETS Nasdaq
- ACRS Nasdaq
- Market Cap
- PETS 62.8M
- ACRS 165.7M
- IPO Year
- PETS N/A
- ACRS 2015
- Fundamental
- Price
- PETS $3.40
- ACRS $1.44
- Analyst Decision
- PETS Sell
- ACRS Strong Buy
- Analyst Count
- PETS 2
- ACRS 8
- Target Price
- PETS $3.35
- ACRS $9.71
- AVG Volume (30 Days)
- PETS 141.6K
- ACRS 1.3M
- Earning Date
- PETS 08-05-2025
- ACRS 08-06-2025
- Dividend Yield
- PETS N/A
- ACRS N/A
- EPS Growth
- PETS N/A
- ACRS N/A
- EPS
- PETS 0.02
- ACRS N/A
- Revenue
- PETS $247,010,000.00
- ACRS $17,777,000.00
- Revenue This Year
- PETS N/A
- ACRS N/A
- Revenue Next Year
- PETS N/A
- ACRS $11.77
- P/E Ratio
- PETS $192.80
- ACRS N/A
- Revenue Growth
- PETS N/A
- ACRS N/A
- 52 Week Low
- PETS $2.90
- ACRS $1.05
- 52 Week High
- PETS $6.85
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PETS 39.83
- ACRS 49.27
- Support Level
- PETS $3.13
- ACRS $1.38
- Resistance Level
- PETS $3.44
- ACRS $1.52
- Average True Range (ATR)
- PETS 0.18
- ACRS 0.10
- MACD
- PETS -0.02
- ACRS -0.01
- Stochastic Oscillator
- PETS 29.63
- ACRS 31.09
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.